Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hira Rizvi"'
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Autor:
Alexander Drilon, David Hoyos, M. Offin, Jia Luo, Paul K. Paik, A. Iqbal, Chaitanya Bandlamudi, Kathryn C. Arbour, Matthew D. Hellmann, Marjorie G. Zauderer, Benjamin D. Greenbaum, Marta Łuksza, Mark T.A. Donoghue, Kenneth K.-S. Ng, Bob T. Li, R.M. Daly, Adam J. Schoenfeld, Hira Rizvi, Helena A. Yu, Isabel Ruth Preeshagul, Caroline G. McCarthy, Jamie E. Chaft, Charles M. Rudin, Gregory J Riely, Juliana Eng, Jacklynn V. Egger, Azadeh Namakydoust, W.V. Lai, Mark G. Kris, Christina Falcon, Piro Lito
Publikováno v:
Annals of Oncology
Structured Abstract Background Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during thi
Autor:
Andrew J. Plodkowski, Dung T. Le, Juan C. Osorio, Jennifer N. Durham, Hira Rizvi, Helena A. Yu, Michelle S. Ginsberg, Gregory J. Riely, Jamie E. Chaft, Luis A. Diaz, Peter Sawan, Joseph G. Crompton, Azadeh Namakydoust, Kathryn C. Arbour, Matthew D. Hellmann, Darragh Halpenny, Barzin Y. Nabet
Publikováno v:
J Clin Oncol
PURPOSE Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contribu
Autor:
Mark G. Kris, Shirish M. Gadgeel, Hira Rizvi, Helena A. Yu, Adam J. Schoenfeld, G. J. Riely, Jeffrey Girshman, A. Iqbal, Kathryn C. Arbour, Matthew D. Hellmann
Publikováno v:
Annals of Oncology
Background Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitor
Autor:
Victor Vaz, John V. Heymach, Natalie I. Vokes, Liam F. Spurr, Jacklynn V. Egger, Biagio Ricciuti, Subba R. Digumarthy, Andrew D. Cherniack, Ferdinandos Skoulidis, Andrew J. Plodkowski, Michael Y. Tolstorukov, Xinan Wang, Jessica J. Lin, Nuno Vaz, Jianjun Zhang, Gonzalo Recondo, Deepti Venkatraman, Justin F. Gainor, David A. Barbie, Giuseppe Lamberti, Mehmet Altan, Yvonne Y. Li, Lingzhi Hong, Lynette M. Sholl, Hye Sun Park, Kathryn C. Arbour, Matthew D. Hellmann, Mark M. Awad, Mizuki Nishino, Amir Vajdi, Joao Victor Machado Alessi, Hira Rizvi, Sara Khosrowjerdi
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 17(3)
Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibiti
Autor:
Maria E. Arcila, Charles M. Rudin, Glenn Heller, Adam J. Schoenfeld, Gregory J. Riely, Marc Ladanyi, Jessica Flynn, Hira Rizvi, Mark G. Kris, Helena A. Yu, Noura J. Choudhury, Christina Falcon
Publikováno v:
Clin Cancer Res
Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies are under development. We sought to describe treatment outcomes and genomic and immunophenotypic characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ab74d61f0f759a9ab027ae10ff52f8
https://europepmc.org/articles/PMC8127357/
https://europepmc.org/articles/PMC8127357/
Autor:
Maria E. Arcila, Marc Ladanyi, Mark G. Kris, Piro Lito, Andrea Knezevic, Charles M. Rudin, Andrew J. Plodkowski, Gregory J. Riely, Kathryn C. Arbour, Matthew D. Hellmann, Hira Rizvi, Helena A. Yu, Glenn Heller
Publikováno v:
Clin Cancer Res
Purpose: KRAS mutations are identified in approximately 30% of patients with non–small cell lung cancer (NSCLC). Novel direct inhibitors of KRAS G12C have shown activity in early-phase clinical trials. We hypothesized that patients with KRAS G12C m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef3e399cd666fae324945722c2d7124
https://europepmc.org/articles/PMC8771577/
https://europepmc.org/articles/PMC8771577/
Autor:
L. Cambridge, M.K. Kasler, Stephanie Fish, Dennis Stephens, Carlos J. Rodriguez, Hira Rizvi, R. Pollina, Jamie E. Chaft, Juan C. Osorio, Taha Merghoub, Matthew D. Hellmann, Jedd D. Wolchok, Charles M. Rudin, Ai Ni
Publikováno v:
Annals of Oncology. 28:583-589
Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs) can occur. Autoimm
Autor:
Alexander V Penson, Gregory J. Riely, Álvaro Quintanal-Villalonga, Marc Ladanyi, Megan Tenet, Mark G. Kris, Matthew D. Hellmann, Yahya Daneshbod, Joseph M. Chan, Hira Rizvi, Maria E. Arcila, Helena A. Yu, Charles M. Rudin, Dana Pe'er, Michael Offin, Ronglai Shen, Natasha Rekhtman
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 14(10)
Introduction EGFR-mutant lung cancers are clinically and genomically heterogeneous with concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations identifying a subset at increased risk for small cell transformation. The g
Autor:
Jesse M. Zaretsky, Jacklin Gukasyan, John Madrigal, James M. Carroll, David Elashoff, Steven M. Dubinett, Jonathan W. Goldman, Daniel K. Wells, I. Peter Shintaku, Edward B. Garon, Antoni Ribas, Hira Rizvi, Benjamin P Jones, Dennis J. Slamon, Siwen Hu-Lieskovan, Aaron Lisberg, Matthew D. Hellmann, Tristan Grogan, Amy L. Cummings
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(16)
Purpose: Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), and CD8 cells in melanoma. We sought to examine the relationship